Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
R&D Partner Content 5th Gene Therapy for Ophthalmic Disorders Summit Ophthalmic drug developers are unlocking the full potential of gene therapy.
Partner Content Partner Content Exclusive interview with ForwardVue Pharma released for Opht... Exclusive interview with ForwardVue Pharma
Partner Content Partner Content Ophthalmic Drug Delivery Development - Trials and Tribulatio... Ophthalmic Drug Delivery Development Workshop
Partner Content Partner Content Novel Platforms in Ocular Drug Delivery workshop discussed a... Novel Platforms in Ocular Drug Delivery workshop
Partner Content Partner Content Aerie Pharmaceuticals interview released for Ophthalmic Drug... Ophthalmic Drugs
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.